Trial Profile

A Double Blind Placebo Controlled Study to Evaluate the Effects of Bexagliflozin on Hemoglobin A1c in Patients With Type 2 Diabetes and Increased Risk of Cardiovascular Adverse Events

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 12 Jan 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bexagliflozin (Primary)
Indications Type 2 diabetes mellitus
Focus Registrational; Therapeutic Use
Acronyms BEST
Sponsors Theracos

Most Recent Events

15 Jun 2021 Status changed from active, no longer recruiting to completed.
03 Nov 2020 This trial has been completed in Netherlands, according to European Clinical Trials Database record.
16 Jun 2020 Primary endpoint (Change in HbA1c from baseline to week 24) has been met, according to results presented at the 80th Annual Scientific Sessions of the American Diabetes Association

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com